Sign in
VERV Stock Price, Chart, Stats & News
Verve Therapeutics, Inc.
Save
994.04M
Market cap
–
Current P/E
–
Forward P/E
VERV chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 100.00% |
Operating margin | -282.71% |
Pretax margin | -247.43% |
Net margin | -247.92% |
Effective tax rate | -0.20% |
ROA | -21.36% |
ROE | -26.68% |
D/E | 0.14x |
Interest coverage ratio | – |
VERV valuation
P/E | – |
P/S | 18.78x |
P/B | 2.09x |
P/CF | -9.13x |
P/FCF | -8.89x |
P/OCF | -9.13x |
PEG | -0.74x |
EV multiple | -7.08x |
About
Verve Therapeutics, Inc. is a biotechnology firm dedicated to pioneering gene-editing treatments for individuals afflicted with cardiovascular diseases. Their flagship experimental therapy, VERVE-101, represents a singular gene-editing intervention engineered to irreversibly inactivate the PCSK9 gene within the liver. The company is also progressing with an ANGPTL3 program, which similarly aims to permanently switch off the ANGPTL3 gene in the liver.
Similar securities
Based on sector and market capitalization
Report issue